Guideline sources The following summarized guidelines for the management of pneumococcal vaccination in adults are prepared by our editorial team based on guidelines from the Center for Disease Control (CDC 2022; 2019). 1 2 Guidelines 1. Preventative measures Schedules: Offer 1 dose of pneumococcal conjugate vaccine (either PCV20 or PCV15) in adults aged 19-64 years with certain underlying medical conditions or other risk factors not previously received pneumococcal conjugate vaccine or if previous vaccination history is unknown. E Offer 1 dose of pneumococcal conjugate vaccine (either PCV20 or PCV15) in adults aged 65 years not previously received pneumococcal conjugate vaccine or if previous vaccination history is unknown. E Offer 1 dose of PPSV23 in all adults aged 65. E Show 4 more Timing and intervals: Offer 1 dose of PPSV23 1 year after PCV15, if it was used, in adult patients aged 19 years. E Show 3 more Administer PCV13, if such a decision is made, before PPSV23. Keep 1-year intervals between pneumococcal vaccines, regardless of the order in which they were received, in adults without an immunocompromising condition, CSF leak, or cochlear implant. E Show 2 more https://web.pathway.md/diseases/recOhLwWeXMszbE3V 1/2 6/29/23, 11:15 PM Pneumococcal vaccination in adults Pathway References 1. Almea Matanock, Grace Lee, Ryan Gierke et al. Use of 13 Valent Pneumococcal Conjugate Vaccine and 23 Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged 65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019 Nov 22;68 46 1069 1075. Open 2. Miwako Kobayashi, Jennifer L Farrar, Ryan Gierke et al. Use of 15 Valent Pneumococcal Conjugate Vaccine and 20 Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices United States, 2022. MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71 4 109 117. Open https://web.pathway.md/diseases/recOhLwWeXMszbE3V 2/2